Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Axcella Health Inc (AXLA)

Axcella Health Inc (AXLA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 186,724
  • Shares Outstanding, K 37,722
  • Annual Sales, $ 0 K
  • Annual Income, $ -56,530 K
  • 60-Month Beta 1.39
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.14
Trade AXLA with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.41
  • Number of Estimates 6
  • High Estimate -0.35
  • Low Estimate -0.46
  • Prior Year -0.48
  • Growth Rate Est. (year over year) +14.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.03 +57.43%
on 05/26/21
5.90 -19.15%
on 06/10/21
+1.41 (+41.96%)
since 05/14/21
3-Month
3.03 +57.43%
on 05/26/21
5.90 -19.15%
on 06/10/21
-1.08 (-18.46%)
since 03/12/21
52-Week
3.03 +57.43%
on 05/26/21
6.84 -30.26%
on 02/10/21
-0.25 (-4.98%)
since 06/12/20

Most Recent Stories

More News
Thinking about buying stock in Mereo BioPharma, Lipocine, Lordstown Motors, Sorrento Therapeutics, or Axcella Health?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MREO, LPCN, RIDE, SRNE, and AXLA.

AXLA : 4.77 (-3.64%)
MREO : 3.37 (+5.97%)
RIDE : 9.26 (-18.84%)
LPCN : 1.3900 (+4.51%)
SRNE : 9.46 (+6.65%)
Flagship Pioneering Closes $3.4 Billion Capital Pool to Drive Continued Breakthrough Innovations in Human Health and Sustainability

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced a significant expansion of its capital base to support founding and growing its next generation of human health...

FHTX : 11.94 (+1.02%)
SANA : 24.67 (+4.71%)
SGTX : 11.19 (+2.85%)
AXLA : 4.77 (-3.64%)
CDAK : 25.55 (-4.70%)
EVLO : 16.34 (+9.15%)
KLDO : 6.84 (+1.33%)
MRNA : 207.41 (-5.23%)
RUBY : 28.43 (+3.01%)
MCRB : 20.66 (+0.58%)
Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture

, /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental...

AXLA : 4.77 (-3.64%)
CDAK : 25.55 (-4.70%)
DNLI : 75.06 (+0.08%)
EVLO : 16.34 (+9.15%)
FHTX : 11.94 (+1.02%)
KLDO : 6.84 (+1.33%)
MCRB : 20.66 (+0.58%)
MRNA : 207.41 (-5.23%)
RUBY : 28.43 (+3.01%)
SANA : 24.67 (+4.71%)
SGTX : 11.19 (+2.85%)
Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus Greening

, /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental...

AXLA : 4.77 (-3.64%)
CDAK : 25.55 (-4.70%)
DNLI : 75.06 (+0.08%)
EVLO : 16.34 (+9.15%)
FHTX : 11.94 (+1.02%)
KLDO : 6.84 (+1.33%)
MCRB : 20.66 (+0.58%)
MRNA : 207.41 (-5.23%)
RUBY : 28.43 (+3.01%)
SANA : 24.67 (+4.71%)
SGTX : 11.19 (+2.85%)
S&P Reaches New Record Ahead of Big Bank Reports

S&P Reaches New Record Ahead of Big Bank Reports

JPM : 157.57 (-1.70%)
WFC : 45.15 (-1.16%)
GS : 372.92 (-1.36%)
VMC : 171.73 (-1.44%)
AXLA : 4.77 (-3.64%)
NVAX : 207.71 (-0.94%)
TWST : 112.77 (-1.62%)
TAL : 29.82 (+2.02%)
ILMN : 452.14 (-0.23%)
NEO : 43.57 (+1.09%)
HTHT : 56.94 (+0.21%)
LVS : 54.15 (-2.66%)
TDC : 47.05 (-1.47%)
JNJ : 165.37 (+0.25%)
Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial Officer

, /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental...

AXLA : 4.77 (-3.64%)
CDAK : 25.55 (-4.70%)
DNLI : 75.06 (+0.08%)
EVLO : 16.34 (+9.15%)
FHTX : 11.94 (+1.02%)
KLDO : 6.84 (+1.33%)
MRNA : 207.41 (-5.23%)
RUBY : 28.43 (+3.01%)
SANA : 24.67 (+4.71%)
MCRB : 20.66 (+0.58%)
SGTX : 11.19 (+2.85%)
Late Rally Snaps Market's Two-Day Skid

Late Rally Snaps Market's Two-Day Skid

DT : 56.16 (+1.30%)
AUDC : 33.68 (+0.75%)
KLIC : 56.65 (-0.25%)
NBIX : 99.62 (+1.02%)
AXLA : 4.77 (-3.64%)
ONCT : 5.49 (+1.29%)
GRPN : 43.92 (-5.12%)
REAL : 20.39 (+0.25%)
LQDT : 22.58 (-1.35%)
MOGO : 7.20 (+0.70%)
FLL : 9.82 (-0.30%)
MGNI : 31.83 (-3.11%)
ACLS : 41.75 (+0.58%)
IRDM : 39.80 (+1.89%)
CVET : 27.63 (+1.02%)
Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target

, /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it raised in Series B financing....

AXLA : 4.77 (-3.64%)
CDAK : 25.55 (-4.70%)
DNLI : 75.06 (+0.08%)
EVLO : 16.34 (+9.15%)
FHTX : 11.94 (+1.02%)
KLDO : 6.84 (+1.33%)
MRNA : 207.41 (-5.23%)
RUBY : 28.43 (+3.01%)
SANA : 24.67 (+4.71%)
MCRB : 20.66 (+0.58%)
SGTX : 11.19 (+2.85%)
Axcella Announces Upcoming Presentation at J.P. Morgan Healthcare Conference

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced...

JPM : 157.57 (-1.70%)
AXLA : 4.77 (-3.64%)
Why Axcella (AXLA) Might Surprise This Earnings Season

Axcella (AXLA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

AXLA : 4.77 (-3.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Axcella Health Inc. is a biotechnology company. It is engaged in the research and development of novel multifactorial interventions to support health and address dysregulated metabolism. The company's principal candidate consists of AXA1665, AXA1125, AXA1957, AXA2678 and AXA4010 which are in clinical...

See More

Key Turning Points

3rd Resistance Point 5.61
2nd Resistance Point 5.39
1st Resistance Point 5.08
Last Price 4.77
1st Support Level 4.55
2nd Support Level 4.33
3rd Support Level 4.02

See More

52-Week High 6.84
Fibonacci 61.8% 5.38
Fibonacci 50% 4.93
Last Price 4.77
Fibonacci 38.2% 4.49
52-Week Low 3.03

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar